VERIFY RECORD
Abridge
4 of 10 claims verified
4 of 10 claims verified, 2 plausible, 4 thin, 0 contradicted. No confirmed 2026 revenue figure and no official headcount disclosure.
Claims
- [verified]
Founded 2018 in Pittsburgh by cardiologist Dr. Shiv Rao (with co-founder Zachary Lipton, a CMU professor); Rao remains CEO
TechCrunch calls it '7-year-old Abridge' as of June 2025; Contrary Research dates founding to March 2018 and names Rao, Metze, and Konam as founders, with Rao the only founder still on the executive team as of March 2025.
- [verified]
$300M Series E at $5.3B valuation, led by Andreessen Horowitz with Khosla Ventures, closed June 2025 (roughly double the $2.75B valuation from the $250M Series D four months earlier)
Confirmed by TechCrunch reporting and Abridge's own company blog post announcing the round; Sacra corroborates the prior $250M/$2.75B Series D.
- [verified]
$117M in contracted annual recurring revenue (Q1 2025), up from ~$60M ARR at end of 2024 and ~$100M ARR by May 2025
TechCrunch reports the $117M contracted-ARR figure directly attributed to the company for Q1 2025. This is the most recent revenue figure found; no confirmed 2026 ARR figure exists (see gaps).
- [verified]
NVIDIA co-developing a foundation model for clinical conversations, and Eli Lilly made a strategic investment to use Abridge conversations for clinical-trial recruitment, announced June 2026
Corroborated across three independent outlets (Fortune, Healthcare Dive, Endpoints News) covering the same June 2026 announcement.
- [plausible]
Health system footprint grew from '150+ enterprise health systems' (per Abridge's own June 2025 Series E announcement) to 'more than 300 health systems' including Northwestern Medicine, Emory Healthcare, and Johns Hopkins (per June 2026 coverage)
Directionally consistent growth across two dated, company-linked disclosures a year apart, but the '300+' figure traces to a single press cluster (Fortune/Healthcare Dive covering the same announcement) rather than independent counts.
- [plausible]
Annual clinical conversation volume roughly doubled from '50 million medical conversations' (2025, per Abridge's own blog) to 'upward of 100 million clinical conversations annually' (2026, per press coverage)
The 2026 figure comes from the same Fortune/Healthcare Dive press cluster, not an independently disclosed company metric.
- [thin]
$316M Series E extension in April 2026, maintaining the $5.3B valuation, bringing total funding to roughly $830M
Explicitly sourced to secondary market-data providers, not a direct Abridge company announcement; no primary confirmation found.
- [thin]
Abridge platform 'serves more than 250 million patients'
Single-source figure from the June 2026 press cluster; ambiguous whether this counts patients directly documented by Abridge or the total addressable patient population of client health systems' networks.
- [thin]
Headcount is roughly 500-635 employees as of mid-2026
No official company headcount disclosure found. Third-party estimation firms disagree materially by date/source (Contrary Research: 280 as of Sept 2025; other trackers cited in search results ranged 539-635 for late 2025/2026), so treated as thin pending a primary source.
- [thin]
Self-reported clinical impact metrics: reduces documentation burden/burnout by 60-70%, automates 91% of medical note creation, and 90%+ of clinicians who start using Abridge continue using it
These are company-originated efficacy claims relayed via Abridge's own blog and a research aggregator; no independent clinical study or third-party audit was found verifying them.
Gaps
- No confirmed 2026 ARR/revenue figure; the most recent disclosed figure is $117M contracted ARR from Q1 2025.
- No primary-source (company-disclosed) headcount figure; only conflicting third-party employee-tracking estimates.
- The $316M Series E extension (April 2026) lacks a primary company announcement; sourced only to secondary market-data trackers.
- Could not locate independent (non-company-linked) verification of the clinical efficacy percentages (burnout reduction, note-automation rate, retention rate).